Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18351087 | HLA-RESTRICTED EPITOPES ENCODED BY SOMATICALLY MUTATED GENES | Non-Final OA | The Johns Hopkins University |
| 18238045 | METHODS FOR REDUCING ALLERGIES CAUSED BY ENVIRONMENTAL ALLERGENS | Non-Final OA | Société des Produits Nestlé S.A. |
| 17627212 | CHIMERIC HEMAGGLUTININ PROTEIN AND A VACCINE COMPOSITION COMPRISING THE SAME | Non-Final OA | ACADEMIA SINICA |
| 18344142 | Particle Formation And Morphology | Non-Final OA | Elektrofi, Inc. |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | Non-Final OA | Baylor College of Medicine |
| 18066132 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | Non-Final OA | CITY OF HOPE |
| 17438496 | ANTI-HLA-DQ2.5 ANTIBODY | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 16938214 | IMMUNORECEPTOR MODULATION FOR TREATING CANCER AND VIRAL INFECTIONS | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Mammoth Biosciences, Inc. |
| 18236327 | T CELL RECEPTORS AND USES THEREOF | Non-Final OA | MEDIGENE IMMUNOTHERAPIES GMBH |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18107244 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF | Non-Final OA | Cue Biopharma, Inc. |
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | Non-Final OA | Cure Genetics Co., Limited |
| 17995299 | CORONAVIRUS VACCINE | Non-Final OA | PepTC Vaccines Limited |
| 17777255 | RIG-I AGONIST AND ADJUVANT FORMULATION FOR TUMOR TREATMENT | Non-Final OA | ACCESS TO ADVANCED HEALTH INSTITUTE |
| 17608878 | HIGH YIELD PRODUCTION AND USE OF ENZYMATIC-EXCHANGEABLE PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I SINGLE CHAIN TRIMER TETRAMER | Non-Final OA | ImmunoSCAPE Pte. Ltd. |
| 17327733 | METHOD FOR BLOCKING ANTIBODY ADMINISTRATION IN TRANSPLANTATION | Final Rejection | National Institute of Transplantation Foundation |
| 17028762 | Nucleic Acids for Treatment of Allergies | Non-Final OA | Immunomic Therapeutics, Inc |
| 15316584 | Determining Antigen Recognition through Barcoding of MHC Multimers | Non-Final OA | Immudex ApS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy